KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Equity Average (2016 - 2025)

Historic Equity Average for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to $596.7 million.

  • Xenon Pharmaceuticals' Equity Average fell 2730.85% to $596.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $596.7 million, marking a year-over-year decrease of 2730.85%. This contributed to the annual value of $841.4 million for FY2024, which is 202.53% up from last year.
  • According to the latest figures from Q3 2025, Xenon Pharmaceuticals' Equity Average is $596.7 million, which was down 2730.85% from $669.0 million recorded in Q2 2025.
  • In the past 5 years, Xenon Pharmaceuticals' Equity Average ranged from a high of $907.8 million in Q1 2024 and a low of $223.8 million during Q1 2021
  • Over the past 5 years, Xenon Pharmaceuticals' median Equity Average value was $669.0 million (recorded in 2025), while the average stood at $632.6 million.
  • As far as peak fluctuations go, Xenon Pharmaceuticals' Equity Average surged by 20417.97% in 2022, and later crashed by 2730.85% in 2025.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Equity Average stood at $399.5 million in 2021, then skyrocketed by 84.56% to $737.3 million in 2022, then increased by 6.1% to $782.3 million in 2023, then dropped by 0.75% to $776.4 million in 2024, then dropped by 23.14% to $596.7 million in 2025.
  • Its Equity Average was $596.7 million in Q3 2025, compared to $669.0 million in Q2 2025 and $729.4 million in Q1 2025.